DarioHealth Granted Another U.S. Patent Strengthening its Core Technology

CAESAREA, Israel, Dec. 27, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced the U.S. Patent and Trademark Office has issued the Company patent #9832301 titled "Systems and Methods for Adjusting Power Levels on a Monitoring Device."

DarioHealth uses this patented technology to enhance the way its smart meter communicates with users' smartphone devices. In the U.S. market, the Dariotm Blood Glucose Monitoring System connects to a smartphone via a coin-sized dongle that does not require a battery for operation; rather, it relies on the smartphone's battery as its power source. In the effort to reduce battery-dependence and ensure 100% real-time data capture, the application is able to monitor and adjust power levels on smartphones accordingly to enable sufficient output with minimal reliance.

Dror Bacher, COO and Vice President of R&D at DarioHealth, commented, "We are very excited to finish off 2017 with this news. This patent has already been part and parcel of the Dario Blood Glucose Monitoring System since it entered the U.S. market and showcases our commitment to further enhancing our core technologies on our native mobile solutions.

"With this patent, DarioHealth strengthens its IP rights and enables us to be compatible with more devices. DarioHealth is a unique company that is building value for its investors, as it continues to make new technological applications in the chronic disease management space in general and specifically in the diabetes space."

About DarioHealth Corp.

DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dariotm Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, the content of which is not part of this news release, visit http://mydario.investorroom.com/.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when it describes further enhancing its core technologies on its native mobile solutions and building value for its investors, as it continues to make new technological applications in the chronic disease management space in general and specifically in the diabetes space. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dariotm as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

DarioHealth Corporate Contact: Shmuel Herschberg, Marketing Director, [email protected], 1-914-775-5548

DarioHealth Public Relations Contact: Terese Kelly, Rosica PR, [email protected], 1-201-843-5600

DarioHealth Investor Relations Contact: Stephen Hart, Hayden IR, [email protected], 1-917-658-7878

SOURCE DarioHealth Corp.